Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29(8):2104-14. https://doi.org/10.1007/s11095-012-0739-z

Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long- acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes, Obesity Metab 2012;14(10):944-50. https://doi.org/10.1111/j.1463-1326.2012.01638.x

Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes, Obesity Metab 2012;14(9):859-64.

Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017; 377(8):723-32. https://doi.org/10.1056/NEJMoa1615692

Landstedt-Hallin L. Changes in HbA1c, insulin dose and incidence of hypoglycemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting: an observational study. Curr Med Res Opin 2015;31(8):1487-93. https://doi.org/10.1185/03007995.2015.1058252

Goldenberg RM, Aroda VR, Billings LK, et al. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes Obes Metab 2021;23(11):2572-81. https://doi.org/10.1111/dom.14504